Multiple Sclerosis Trust
As well as delivering verdicts on the use of drugs in the NHS, for example beta interferon and glatiramer acetate for the treatment of MS, NICE (the National Institute for Clinical Evidence) also produces Guidelines and in 2000 was asked by the Department of Health to consider the management of MS.
The guideline development process has involved searching through and evaluating in a systematic manner the published evidence on the treatment of MS. Where there is no evidence, a panel of experts have made recommendations on the basis of consensus. The panel was drawn from health professionals specialising in MS, and a representative each from the MS Trust and the MS Society.
The MS Trust has been a stakeholder during the three year process, representing the views of people with MS and submitting documents based on the comments of a number of people who have responded to the drafts of the guidelines as they have become available.
In March 2003, three draft versions were made available on the NICE website for public consultation:
These clinical guidelines will make key recommendations for service
improvement for the management of MS in England and Wales. They will act
as a benchmark for best practice by which all who are involved in MS -
whether personally or professionally – will, we hope, be able to work together
for better services.
Copyright © 2003, Multiple Sclerosis Trust